Teva fails to reclassify MS drug to thwart generics
05-01-2021
Photo: Courtesy of Teva
Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva; Allergan; Allergan Generics; ANDA; generics; mergers and acquisitions; Erez Vigodman; Brent Saunders; FDA; Actavis
